Aurinia Pharmaceuticals (AUPH) Stock Analysis & AI Equity Report
Aurinia Pharmaceuticals (AUPH) overview
Aurinia Pharmaceuticals (AUPH) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 283m and operating profit of USD 105m; the year-end share price was 15.95 USD and market capitalisation was USD 2,111m. Aurinia Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Aurinia Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company focused on therapies for autoimmune diseases. It markets LUPKYNIS, an oral therapy for adults with active lupus nephritis, directly through its U.S. commercial organization and sells it to specialty pharmacies and a specialty distributor. Collaboration partner Otsuka markets the product in Japan, the European Union, the United Kingdom and Switzerland.
Generate the Aurinia Pharmaceuticals report
Aurinia Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Aurinia Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Aurinia Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.